Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

News feed

Shareholders of EvroTrans approved dividends

10/1/25 EUTR

Ozon Pharmaceuticals places shares in the framework of the second stage of the SPO

10/1/25 OZPH

Etalon received a land plot in the Kaliningrad region

10/1/25 ETLN

VKontakte has integrated shopping into the feed with the help of shops

10/1/25 VKCO

VTB's retail business was headed by Olga Skorobogatova

10/1/25 VTBR

SPB Exchange summed up the results of trading in September

10/1/25 SPBE

Polyplast Group of Companies has agreed to cooperate with Naftan

10/1/25 -

SPB Exchange will present the futures market at Finopolis

10/1/25 SPBE

Softline acquired a controlling stake in BeringPro

10/1/25 SOFL

MD Medical Board of Directors announces dividends

10/1/25 MDMG